STAT3 inhibition sensitizes colorectal cancer to chemoradiotherapy in vitro and in vivo

International Journal of Cancer

Volumn 134, Issue 4, 2014, Pages 997-1007

  Spitzner, Melanie ^a   Roesler, Birte ^a   Bielfeld, Christian ^a   Emons, Georg ^a   Gaedcke, Jochen ^a   Wolff, Hendrik A ^a   Rave Fränk, Margret ^a   Kramer, Frank ^a   Beissbarth, Tim ^a   Kitz, Julia ^a   Wienands, Jürgen ^a   Ghadimi, B Michael ^a   Ebner, Reinhard ^b   Ried, Thomas ^b   Grade, Marian ^a  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

chemoradiotherapy resistance; chemoradiotherapy sensitization; molecular target; rectal cancer; STAT3

Indexed keywords

FLUOROURACIL; INTERLEUKIN 6; LUCIFERASE; MESSENGER RNA; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; STAT3 PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER RADIOTHERAPY; CANCER RESISTANCE; CANCER SURVIVAL; CELL VIABILITY; CHEMORADIOTHERAPY; COLORECTAL CANCER; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENE SILENCING; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; IN VIVO STUDY; INHIBITION KINETICS; IRRADIATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RNA INTERFERENCE; STAT3 GENE; TUMOR GENE; WESTERN BLOTTING;

EID: 84890128532     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28429     Document Type: Article

References (50)

1. Yu H, Jove R,. The STATs of cancer-new molecular targets come of age. Nat Rev Cancer 2004; 4: 97-105.
2. Haura EB, Turkson J, Jove R,. Mechanisms of disease: insights into the emerging role of signal transducers and activators of transcription in cancer. Nat Clin Pract Oncol 2005; 2: 315-24.
3. Bromberg JF, Wrzeszczynska MH, Devgan G, et al. Stat3 as an oncogene. Cell 1999; 98: 295-303.
4. Darnell JE, Jr., STATs and gene regulation. Science 1997; 277: 1630-5.
5. Yu H, Kortylewski M, Pardoll D,. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat Rev Immunol 2007; 7: 41-51.
6. Yu H, Pardoll D, Jove R,. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer 2009; 9: 798-809.
7. Grivennikov SI, Greten FR, Karin M,. Immunity, inflammation, and cancer. Cell 2010; 140: 883-99.
8. Sansone P, Bromberg J,. Targeting the interleukin-6/Jak/stat pathway in human malignancies. J Clin Oncol 2012; 30: 1005-14.
9. Spitzner M, Emons G, Kramer F, et al. A gene expression signature for chemoradiosensitivity of colorectal cancer cells. Int J Radiat Oncol Biol Phys 2010; 78: 1184-92.
10. Cunningham D, Atkin W, Lenz HJ, et al. Colorectal cancer. Lancet 2010; 375: 1030-47.
11. Rodel C, Hofheinz R, Liersch T,. Rectal cancer: state of the art in 2012. Curr Opin Oncol 2012; 24: 441-7.
12. Grade M, Hummon AB, Camps J, et al. A genomic strategy for the functional validation of colorectal cancer genes identifies potential therapeutic targets. Int J Cancer 2011; 128: 1069-79.
13. Schust J, Sperl B, Hollis A, et al. Stattic: a small-molecule inhibitor of STAT3 activation and dimerization. Chem Biol 2006; 13: 1235-42.
14. Livak KJ, Schmittgen TD,. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001; 25: 402-8.
15. Kendziorra E, Ahlborn K, Spitzner M, et al. Silencing of the Wnt transcription factor TCF4 sensitizes colorectal cancer cells to (chemo-) radiotherapy. Carcinogenesis 2011; 32: 1824-31.
16. Scuto A, Kujawski M, Kowolik C, et al. STAT3 inhibition is a therapeutic strategy for ABC-like diffuse large B-cell lymphoma. Cancer Res 2011; 71: 3182-8.
17. Lin Q, Lai R, Chirieac LR, et al. Constitutive activation of JAK3/STAT3 in colon carcinoma tumors and cell lines: inhibition of JAK3/STAT3 signaling induces apoptosis and cell cycle arrest of colon carcinoma cells. Am J Pathol 2005; 167: 969-80.
18. Kusaba T, Nakayama T, Yamazumi K, et al. Expression of p-STAT3 in human colorectal adenocarcinoma and adenoma; correlation with clinicopathological factors. J Clin Pathol 2005; 58: 833-8.
19. Corvinus FM, Orth C, Moriggl R, et al. Persistent STAT3 activation in colon cancer is associated with enhanced cell proliferation and tumor growth. Neoplasia 2005; 7: 545-55.
20. Morikawa T, Baba Y, Yamauchi M, et al. STAT3 expression, molecular features, inflammation patterns, and prognosis in a database of 724 colorectal cancers. Clin Cancer Res 2011; 17: 1452-62.
21. Monnien F, Zaki H, Borg C, et al. Prognostic value of phosphorylated STAT3 in advanced rectal cancer: a study from 104 French patients included in the EORTC 22921 trial. J Clin Pathol 2010; 63: 873-8.
22. Klampfer L,. The role of signal transducers and activators of transcription in colon cancer. Front Biosci 2008; 13: 2888-99.
23. Waldner MJ, Foersch S, Neurath MF,. Interleukin-6-a key regulator of colorectal cancer development. Int J Biol Sci 2012; 8: 1248-53.
24. Atreya R, Neurath MF,. Signaling molecules: the pathogenic role of the IL-6/STAT-3 trans signaling pathway in intestinal inflammation and in colonic cancer. Curr Drug Targets 2008; 9: 369-74.
25. Rose-John S, Mitsuyama K, Matsumoto S, et al. Interleukin-6 trans-signaling and colonic cancer associated with inflammatory bowel disease. Curr Pharm Des 2009; 15: 2095-103.
26. Grade M, Hormann P, Becker S, et al. Gene expression profiling reveals a massive, aneuploidy-dependent transcriptional deregulation and distinct differences between lymph node-negative and lymph node-positive colon carcinomas. Cancer Res 2007; 67: 41-56.
27. Camps J, Nguyen QT, Padilla-Nash HM, et al. Integrative genomics reveals mechanisms of copy number alterations responsible for transcriptional deregulation in colorectal cancer. Genes Chromosomes Cancer 2009; 48: 1002-17.
28. Camps J, Pitt JJ, Emons G, et al. Genetic amplication of the NOTCH modulator LNX2 upregulates the WNT/beta-catenin pathway in colorectal cancer. Cancer Res 2013; 73: 2003-13.
29. Network CGA,. Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012; 487: 330-7.
30. Tsareva SA, Moriggl R, Corvinus FM, et al. Signal transducer and activator of transcription 3 activation promotes invasive growth of colon carcinomas through matrix metalloproteinase induction. Neoplasia 2007; 9: 279-91.
31. Zugowski C, Lieder F, Muller A, et al. STAT3 controls matrix metalloproteinase-1 expression in colon carcinoma cells by both direct and AP-1-mediated interaction with the MMP-1 promoter. Biol Chem 2011; 392: 449-59.
32. Suzuki A, Hanada T, Mitsuyama K, et al. CIS3/SOCS3/SSI3 plays a negative regulatory role in STAT3 activation and intestinal inflammation. J Exp Med 2001; 193: 471-81.
33. Bollrath J, Phesse TJ, von Burstin VA, et al. gp130-mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis. Cancer Cell 2009; 15: 91-102.
34. Grivennikov S, Karin E, Terzic J, et al. IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell 2009; 15: 103-13.
35. Lin L, Liu Y, Li H, et al. Targeting colon cancer stem cells using a new curcumin analogue, GO-Y030. Br J Cancer 2011; 105: 212-20.
36. Lin L, Liu A, Peng Z, et al. STAT3 is necessary for proliferation and survival in colon cancer-initiating cells. Cancer Res 2011; 71: 7226-37.
37. Grade M, Wolff HA, Gaedcke J, et al. The molecular basis of chemoradiosensitivity in rectal cancer: implications for personalized therapies. Langenbecks Arch Surg 2012; 397: 543-55.
38. Kim KW, Mutter RW, Cao C, et al. Inhibition of signal transducer and activator of transcription 3 activity results in down-regulation of Survivin following irradiation. Mol Cancer Ther 2006; 5: 2659-65.
39. Bonner JA, Trummell HQ, Willey CD, et al. Inhibition of STAT-3 results in radiosensitization of human squamous cell carcinoma. Radiother Oncol 2009; 92: 339-44.
40. Gao L, Li F, Dong B, et al. Inhibition of STAT3 and ErbB2 suppresses tumor growth, enhances radiosensitivity, and induces mitochondria-dependent apoptosis in glioma cells. Int J Radiat Oncol Biol Phys 2010; 77: 1223-31.
41. Chen YW, Chen KH, Huang PI, et al. Cucurbitacin I suppressed stem-like property and enhanced radiation-induced apoptosis in head and neck squamous carcinoma-derived CD44(+)ALDH1(+) cells. Mol Cancer Ther 2010; 9: 2879-92.
42. Yang YP, Chang YL, Huang PI, et al. Resveratrol suppresses tumorigenicity and enhances radiosensitivity in primary glioblastoma tumor initiating cells by inhibiting the STAT3 axis. J Cell Physiol 2012; 227: 976-93.
43. Hanahan D, Coussens LM,. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell 2012; 21: 309-22.
44. Swartz MA, Iida N, Roberts EW, et al. Tumor microenvironment complexity: emerging roles in cancer therapy. Cancer Res 2012; 72: 2473-80.
45. Mankan AK, Greten FR,. Inhibiting signal transducer and activator of transcription 3: rationality and rationale design of inhibitors. Expert Opin Investig Drugs 2011; 20: 1263-75.
46. Wang T, Niu G, Kortylewski M, et al. Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat Med 2004; 10: 48-54.
47. Kortylewski M, Kujawski M, Wang T, et al. Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nat Med 2005; 11: 1314-21.
48. Herrmann A, Kortylewski M, Kujawski M, et al. Targeting Stat3 in the myeloid compartment drastically improves the in vivo antitumor functions of adoptively transferred T cells. Cancer Res 2010; 70: 7455-64.
49. Ishihara S, Watanabe T, Kiyomatsu T, et al. Prognostic significance of response to preoperative radiotherapy, lymph node metastasis, and CEA level in patients undergoing total mesorectal excision of rectal cancer. Int J Colorectal Dis 2010; 25: 1417-25.
50. Chang GJ, Rodriguez-Bigas MA, Eng C, et al. Lymph node status after neoadjuvant radiotherapy for rectal cancer is a biologic predictor of outcome. Cancer 2009; 115: 5432-40.